Cool stars in the Galactic center as seen by APOGEE : M giants, AGB stars, and supergiant stars and candidates

The Galactic center region, including the nuclear disk, has until recently been largely avoided in chemical census studies because of extreme extinction and stellar crowding. Large, near-IR spectroscopic surveys, such as the Apache Point Observatory Galactic Evolution Experiment (APOGEE), allow the measurement of metallicities in the inner region of our Galaxy. Making use of the latest APOGEE data release (DR16), we are able for the first time to study cool Asymptotic Giant branch (AGB) stars and supergiants in this region. The stellar parameters of five known AGB stars and one supergiant star (VR 5-7) show that their location is well above the tip of the red giant branch. We studied metallicities of 157 M giants situated within 150 pc of the Galactic center from observations obtained by the APOGEE survey with reliable stellar parameters from the APOGEE pipeline making use of the cool star grid down to 3200 K. Distances, interstellar extinction values, and radial velocities were checked to confirm that these stars are indeed situated in the Galactic center region. We detect a clear bimodal structure in the metallicity distribution function, with a dominant metal-rich peak of [Fe/H] ∼ +0.3 dex and a metal-poor peak around {Fe/H] = −0.5 dex, which is 0.2 dex poorer than Baade’s Window. The α-elements Mg, Si, Ca, and O show a similar trend to the Galactic bulge. The metal-poor component is enhanced in the α-elements, suggesting that this population could be associated with the classical bulge and a fast formation scenario. We find a clear signature of a rotating nuclear stellar disk and a significant fraction of high-velocity stars with vgal >  300 km s−1; the metal-rich stars show a much higher rotation velocity (∼200 km s−1) with respect to the metal-poor stars (∼140 km s−1). The chemical abundances as well as the metallicity distribution function suggest that the nuclear stellar disk and the nuclear star cluster show distinct chemical signatures and might be formed differently

Homogeneous analysis of globular clusters from the APOGEE survey with the BACCHUS code - III. omega Cen

We study the multiple populations of omega Cen by using the abundances of Fe, C, N, O, Mg, Al, Si, K, Ca, and Ce from the high-resolution, high signal-to-noise (S/N > 70) spectra of 982 red giant stars observed by the SDSS-IV/APOGEE-2 survey. We find that the shape of the Al-Mg and N-C anticorrelations changes as a function of metallicity, continuous for the metal-poor groups, but bimodal (or unimodal) at high metallicities. There are four Fe populations, similarly to previous literature findings, but we find seven populations based on Fe, Al, and Mg abundances. The evolution of Al in omega Cen is compared to its evolution in the Milky Way and in five representative globular clusters. We find that the distribution of Al in metal-rich stars of omega Cen closely follows what is observed in the Galaxy. Other alpha-elements and C, N, O, and Ce are also compared to the Milky Way, and significantly elevated abundances are observed over what is found in the thick disc for almost all elements. However, we also find some stars with high metallicity and low [Al/Fe], suggesting that omega Cen could be the remnant core of a dwarf galaxy, but the existence of these peculiar stars needs an independent confirmation. We also confirm the increase in the sum of CNO as a function of metallicity previously reported in the literature and find that the [C/N] ratio appears to show opposite correlations between Al-poor and Al-rich stars as a function of metallicity

2011-2012 UNLV McNair Journal

Journal articles based on research conducted by undergraduate students in the McNair Scholars Program Table of Contents Biography of Dr. Ronald E. McNair Statements: Dr. Neal J. Smatresk, UNLV President Dr. Juanita P. Fain, Vice President of Student Affairs Dr. William W. Sullivan, Associate Vice President for Retention and Outreach Mr. Keith Rogers, Deputy Executive Director of the Center for Academic Enrichment and Outreach McNair Scholars Institute Staf

Evolution of the nuclear spin-orbit splitting explored via the ³²Si<i>(d,p)</i>³³Si reaction using SOLARIS

The spin-orbit splitting between neutron 1p orbitals at 33Si has been deduced using the single-neutron-adding (d,p) reaction in inverse kinematics with a beam of 32Si, a long-lived radioisotope. Reaction products were analyzed by the newly implemented SOLARIS spectrometer at the reaccelerated-beam facility at the National Superconducting Cyclotron Laboratory. The measurements show reasonable agreement with shell-model calculations that incorporate modern cross-shell interactions, but they contradict the prediction of proton density depletion based on relativistic mean-field theory. The evolution of the neutron 1p-shell orbitals is systematically studied using the present and existing data in the isotonic chains of = 17, 19, and 21. In each case, a smooth decrease in the separation of the - orbitals is seen as the respective p-orbitals approach zero binding, suggesting that the finite nuclear potential strongly influences the evolution of nuclear structure in this region

Effective Rheology of Bubbles Moving in a Capillary Tube

We calculate the average volumetric flux versus pressure drop of bubbles moving in a single capillary tube with varying diameter, finding a square-root relation from mapping the flow equations onto that of a driven overdamped pendulum. The calculation is based on a derivation of the equation of motion of a bubble train from considering the capillary forces and the entropy production associated with the viscous flow. We also calculate the configurational probability of the positions of the bubbles.Comment: 4 pages, 1 figur

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding: Sanofi and Regeneron Pharmaceuticals